Clinical significance of MRSA screening and decolonization in infection prevention and control after congenital heart surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063018

Enrollment

Unknown

Registered

2022-08-27

Start date

2022-08-29

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital heart diseases

Interventions

Control group:Receive routine treatment, and check nasal swabs on the 3rd day after admission to CICU

Experimental group:Conventional medical treatment + nasal cavity decolonization treatment

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Children diagnosed with congenital heart disease upon admission; 2. Age < 18 years old; 3. MRSA screening positive; 4. The family members of the children voluntarily participated in this study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Congenital bilateral posterior nasal atresia; 2. Obvious nasal bleeding after operation; 3. Guardian rejects participants.

Design outcomes

Primary

Measure	Time frame
Postoperative infection rate;	—

Secondary

Measure	Time frame
Ventilator time;30-day mortality;Readmission for infection;Length of stay in CICU;CICU hospitalization costs;	—

Countries

China

Contacts

Public ContactXu Zhuoming

Shanghai Children's Medical Center

xi.mo@shsmu.edu.cn+86 21 38626081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026